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DNA methylation in the promoter regions of genes is a prom-
inent epigenetic gene silencing mechanism associated with resis-
tance to endocrine therapy in patients with recurrent breast
cancer. We have employed a microarray-based technology to
investigate the promoter DNA methylation status of 117 candi-
date genes in tumors of breast cancer patients who received
tamoxifen as first-line endocrine treatment for recurrent breast
cancer. Of the genes analyzed, phosphoserine aminotransferase
(PSA-T1) emerged as the strongest marker to predict progres-
sion-free survival. Among the 117 candidate genes, DNA-methyl-
ation markers associated with breast cancer patient outcome
after adjuvant endocrine therapy were also identified and vali-
dated in independent groups of patients. DNA-methylation status
of PITX2 showed the strongest correlation with disease recur-
rence. These results provide validated high-level evidence that
DNA-methylation status allows clinically relevant risk assess-
ment in tamoxifen-treated breast cancer, both in the adjuvant
and palliative setting.
doi:10.1016/j.ejcsup.2006.04.024
S24. MOLECULAR PATHOGENESIS OF PAPILLOMA VIRUS
ASSOCIATED CANCERS
Nicolas Wentzensen. Department of Applied Tumor Biology, Institute
of Pathology, University of Heidelberg, Germany.
A number of human cancers are caused by persistent infections
with high risk human papilloma viruses (HR-HPV), among them
about 100% of cervical cancers, many anogenital cancers, some
head and neck cancers, and a subset of skin cancers. HPVs
infect basal epithelial cells via microlesions and usually replicate
in differentiated superficial epithelial cells. Two HPV oncogenes,
E6 and E7, interfere with the hosts cell cycle and apoptosis reg-
ulation. Most importantly, E7 disrupts the binding of pRb and
E2F and induces continuous cell cycle activation. E6 triggers deg-
radation of p53 and thus abrogates apopotosis. Local immune
defense mechanisms lead to spontaneous clearance of HPV
infections in the majority of cases. In few infections, however,
deregulated expression of E6 and E7 in basal epithelial cells
induces major chromosomal instability and can initiate epithe-
lial transformation. Several characteristic changes have been
identified in epithelial cells transformed by HPV: Strong
p16INK4a expression was found in medium to high grade pre-
malignant lesions as well as in cervical cancer indicating the
functional inactivation of pRb. Proliferation associated markers
like ki67, telomerase, MCM5 and CDC6 are expressed at various
levels in premalignant lesions and invasive cancer. In advanced
lesions, high levels of chromosomal imbalances can be
observed, a very specific alteration is the gain of 3q. Integration
of HPV DNA into the host cell genome specifically indicates
advanced lesions with a high probability of progression and is
frequently found in cervical cancer. Several biomarkers, espe-
cially the detection of HR-HPV DNA and p16INK4a protein, are
currently being evaluated in order to improve existing cervical
cancer screening procedures.
doi:10.1016/j.ejcsup.2006.04.025
S25. DEVELOPING STRATEGIES FOR TUMOR VACCINATION
Andreas Mackensen. Department of Hematology/Oncology,
University of Regensburg, Germany.
Vaccination against cancer has had a variable history, with claims
of success often fading into disappointment. The reasons for this
include poor vaccine design, inadequate understanding of the
nature of the immune response, and a lack of objective measures
to evaluate performance. The characterization of tumor-associ-
ated antigens (TAAs) recognized by human T lymphocytes in a
MHC-restricted fashion has opened new possibilities for specific
vaccine approaches to the treatment of human cancers. Recent
findings include vaccine formulation, relevant knowledge con-
cerning mechanisms of induction of effective immunity from pre-
clinical models, and translation into clinical trials. We now have
novel vaccine strategies to activate specific attack on tumor cells
and we understand more about activation and regulation of
immunity against cancer (co-stimulation versus co-inhibition,
regulatory T cells). We also have modern assays using surrogate
markers (MHC multimer analysis, IFN-c Elispot assay) to correlate
with clinical effects. Although early clinical vaccine trials based
on synthetic peptides, proteins, ‘naked’ DNA, tumor-RNA, den-
dritic cells, and recombinant vaccinia viruses indicate that vac-
cines can induce immune responses and tumor regression in
some cancer patients, careful study design and use of standard-
ized clinical and immunological criteria are needed. Basic princi-
ples of tumor vaccination and clinical trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.026
S26. TARGETING MUC1 WITH LIPOSOMAL BLP25
Martin H. Falk, Karl-Josef Kallen. Merck KGaA, Darmstadt,
Germany.
MUC1 is a mucin glycoprotein expressed by both normal cells and
a wide variety of epithelial carcinomas. Mucins expressed by can-
cer cells have abnormal glycosylation that results in shorter and
simpler carbohydrate chains as well as exposure of normally hid-
den (cryptic) epitopes on the protein backbone. These changes
result in unique antigenicity of cancer cell mucins relative to their
normal cell counterparts and make MUC1 an ideal candidate
antigen for immunotherapy.
L-BLP25 vaccine is an investigational therapeutic cancer vac-
cine being studied for the treatment of epithelial carcinomas.
L-BLP25 vaccine incorporates a synthetic lipopeptide sequence
identical to a portion of the protein backbone of MUC1. The vac-
cine is a liposomal formulation that consists of the synthetic
MUC1 lipopeptide, an immunoadjuvant [monophosphoryl lipid
A (MPL)], and three lipids: cholesterol, dimyristoyl phosphatidyl-
glycerol (DMPG) and dipalmitoyl phosphatidylcholine (DPPC).
The BLP25 lipopeptide provides the antigenic specificity for a T-
cell immune response, while the adjuvant serves to TLR4 to acti-
vate APCs. The liposomal delivery system is thought to ensure
delivery of peptide antigen and adjuvant to the exact same cell
as well as facilitate access to the intracellular antigen presenting
machinery of a cell.
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So far, 168 patients with non-small cell lung cancer (NSCLC) or
prostate cancer have been treated with L-BLP25 vaccine in phase I
or II clinical trials. A randomized phase IIb study was performed
that compared the safety and efficacy of L-BLP25 in patients with
stage IIIB or IV NSCLC against best supportive care (BSC). Data
from this study revealed an overall median survival of 17.4
months for patients on the vaccine arm versus 13 months for
the patients in the BSC arm. Two-year survival was 43% for the
L-BLP25 vaccine arm versus 29% for the BSC arm. The median sur-
vival for patients with locoregional Stage IIIB disease (without
pleural effusion) was 30.6 months in the L-BLP25 arm and 13.3
months for patients in the control arm. Two-year survival was
60% for the L-BLP25 vaccine arm versus 37% for the BSC arm.
Safety data from the phase IIb study showed an incidence of
adverse events similar to those previously reported in L-BLP25
clinical trials, i.e. mild to moderate flu-like symptoms and injec-
tion site reactions. Although the differences in survival were sta-
tistically not significant, these results suggest a survival
advantage in locoregional stage IIIB patients treated with L-
BLP25 vaccine. A phase III trial in unresectable stage III NSCLC
patients will be launched in 2006.
doi:10.1016/j.ejcsup.2006.04.027
S27. SURVIVING – PRECLINICAL RATIONAL AND PRELIMINARY
RESULTS
Ju¨rgen C. Becker, Mads Hald Andersen. Department of Dermatology,
University of Wuerzburg, Germany; Department of Tumor Biology,
Danish Cancer Society, Copenhagen, Denmark.
Prognosis of most disseminated solid tumors remains gloomy
as neither chemotherapeutic nor unspecific immune modula-
tory approaches were able to improve the overall survival of
these patients. Hence, specific immunotherapy has received
increasing attention. Disappointing clinical results, however,
indicate that the choice of suitable antigens is of special impor-
tance. To this end, the inhibitor of apoptosis protein survivin,
which is over-expressed in several tumours but is largely unde-
tectable in adult tissues, appears to be a promising target for
vaccination purposes, since downregulation or loss of expres-
sion is associated with impaired tumour progression. Conse-
quently, heavily pretreated patients suffering from advanced,
therapy-refractory melanoma, pancreatic, cervical or colorectal
cancer were vaccinated with affinity-improved HLA-A1, A2 or
B35-restricted survivin-derived peptide epitope together with
Monatamide ISA-51 in a compassionate use setting. Preliminary
results from an interim analysis of this ongoing clinical trial
demonstrated that patients mounted strong survivin specific T
cell responses as measured by ELISPOT assay and tetramer-
staining. Furthermore, in situ peptide/HLA-A2 multimer staining
confirmed that these survivin reactive cells infiltrated both vis-
ceral and soft tissue metastases. Most importantly, clinical
activity was suggested by both disease stabilisation as well as
objective responses.
doi:10.1016/j.ejcsup.2006.04.028
S28. THE ROLE OF EGFR FAMILY IN PRENEOPLASIA AND LUNG
CANCER; PERSPECTIVES FOR TARGETED THERAPIES AND
SELECTION OF PATIENTS
Fred R. Hirsch. University of Colorado Cancer Center, United States.
The Erb-B family of receptors seems to play an important role in
the lung carcinogenesis. Several studies have demonstrated over
expression of epidermal growth factor receptor (EGFR) in bron-
chial dysplasias.1 We have studied 268 bronchial biopsies from
high-risk individuals participating in a high-risk sputum cohort
(>30 pack-years of smoking history and COPD defined as
FEV1 < 70% of expected), and EGFR protein was strongly
expressed in about 60% of patients with normal bronchial histol-
ogies, but increased with increased level of dysplasia. Also HER2
was highly expressed in both normal bronchial epithelium as well
as in preneoplasias.2
The expression of EGFR/HER2 in malignant lung tumors was
studied in several studies. Squamous cell carcinomas has most
often high expression of EGFR, but less HER2, while adenocarci-
nomas has more often high expression of HER2 and less EGFR.
Of interest is that bronchioloalveolar carcinomas has high
expression of both EGFR and HER2, which can contribute to
explain why this subtype seems to be more sensitive to EGFR
inhibitors than the other non-small cell subtypes.3
The prognostic role of EGFR and HER2 has been addressed.4,5 In
our study 183 patients with resected NSCLC were studied, and no
significant prognostic association was demonstrated in this
study. However, other studies have reported that EGFR overex-
pression is associated with poorer prognosis.5 In the UCCC study
also the EGFR gene copy number was studied by FISH, and a ten-
dency to a shorter survival was seen for increased gene copy
number.4
The predictive role of EGFR and HER2 for sensitivity to EGFR
TKIs has been studied at UCCC in two separate cohorts of NSCLC
patients. In an Italian cohort of 108 NSCLC patients we found that
EGFR protein expression, increased gene copy number detected
by FISH and EGFR gene mutations were all associated to treat-
ment outcome after EGFR TKI therapy.6 Patients with high EGFR
gene copy number (high polysomy/amplification) had a high
objective response rate (36%), disease control rate (67%) and med-
ian survival of 19 months, which was significantly better than the
patients with no or low gene gain. The same was found in another
study cohort (SWOG 0126) for patients with BAC subtypes.7 The
association between increased EGFR gene copy number and sur-
vival has been demonstrated in two randomized placebo con-
trolled studies, one with erlotinib with hazard ratio (HR) = 0.44
in the FISH positive group and in the ISEL study with gefitinib
(HR = 0.61), while no differences was seen in the FISH negative
groups.8,9
In order to identify a panel of markers, which can predict sen-
sitivity to EGFR TKIs we studied the predictive value of combined
markers. While a combination of positive IHC and positive FISH
were associated with very high response rates (41%) and pro-
longed survival (median 21 months), negative IHC and FISH
assessment was associated with no response and very short sur-
vival (median 6months) indicating no clinical benefit in this group
of patients.10 We have also performed in vitro NSCLC cell line
studies with EGFR TKIs and characterized sensitive and resistant
cell lines by Affymetrix gene chips. We have identified several
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